NASDAQ · MAZE

Maze Therapeutics, Inc.

Healthcare · Biotechnology

$28.38▲ 26.75% ($5.99)at close

After hours$28.49▲ 0.39%5:17 PM ET

52-week

$21.95$53.65

Valuation

Recommended · Earnings yield

Price used

$28.38

Earnings yield

0.27%

Reported earnings

10-year Treasury benchmark: 4.97%

USD · Annual earnings · 2024 (EPS fallback)

Trailing earnings are unavailable; the latest annual EPS is used.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: Annual earnings · 2024 (EPS fallback)
Data refreshed: Sep 22, 2026, 9:19 PM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 19.9%Revenue (TTM): 700%FCF (TTM): -0.2%

What changed

The stock rose 19.9% over the last year. Revenue grew 700% over the trailing twelve months. Operating margin moved from -5,033.2% to -728.06%. Free cash flow declined 0.2% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.

What would invalidate this read

Operating margin is at -728.06%. Revenue grew 700% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 0.2%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Monthly returns

Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.

CEOJason Coloma

SectorHealthcare

IndustryBiotechnology

Employees141

IPO dateJan 31, 2025

https://www.mazetx.com

Market multiples

Forward P/E—

EV/EBITDA-12.54

Enterprise value$1.61B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)95.29%

Operating margin (TTM)-728.06%

ROE-37.35%▲10.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$64.00▲125.51%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.79 · Revenue est $333.33K

View